Pfizer Inc. (NYSE:PFE) Shares Purchased by Accel Wealth Management

Accel Wealth Management raised its position in shares of Pfizer Inc. (NYSE:PFE) by 12.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,317 shares of the biopharmaceutical company’s stock after purchasing an additional 932 shares during the period. Accel Wealth Management’s holdings in Pfizer were worth $233,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. City Holding Co. raised its position in shares of Pfizer by 18.9% during the 2nd quarter. City Holding Co. now owns 29,910 shares of the biopharmaceutical company’s stock worth $837,000 after buying an additional 4,744 shares in the last quarter. Cliftonlarsonallen Wealth Advisors LLC raised its holdings in shares of Pfizer by 3.7% in the 2nd quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 18,090 shares of the biopharmaceutical company’s stock worth $506,000 after purchasing an additional 638 shares in the last quarter. Cambridge Advisors Inc. raised its holdings in shares of Pfizer by 17.2% in the 2nd quarter. Cambridge Advisors Inc. now owns 9,368 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 1,375 shares in the last quarter. OLD National Bancorp IN raised its holdings in shares of Pfizer by 17.3% in the 2nd quarter. OLD National Bancorp IN now owns 323,900 shares of the biopharmaceutical company’s stock worth $9,063,000 after purchasing an additional 47,753 shares in the last quarter. Finally, Talbot Financial LLC raised its holdings in shares of Pfizer by 0.4% in the 2nd quarter. Talbot Financial LLC now owns 294,467 shares of the biopharmaceutical company’s stock worth $8,239,000 after purchasing an additional 1,234 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 0.7 %

PFE stock traded down $0.21 during trading hours on Friday, hitting $28.55. The company’s stock had a trading volume of 25,795,602 shares, compared to its average volume of 39,340,824. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.78 and a current ratio of 0.86. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.19. The stock has a 50 day moving average price of $28.80 and a two-hundred day moving average price of $27.87.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.67 earnings per share. Analysts predict that Pfizer Inc. will post 2.68 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.88%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

A number of analysts recently commented on PFE shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $28.00 to $34.00 in a report on Wednesday. UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Wells Fargo & Company boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.